Deciphering the Anti-Leukemic Potential of KW-2449: A Multi-Target Kinase Inhibitor in AML Therapy

3 June 2024
The activation of FLT3 kinase, which is linked to adverse outcomes in AML and affects 30-40% of patients, is targeted by KW-2449, a compound that inhibits multiple kinases including FLT3, FGFR1, Abl, and Abl-T315 with varying IC50 values. It also has a modest effect on c-Src, JAK2, and c-Kit kinases but minimally affects PDGFR, Fms, IGF1R, and EGFR at a concentration of 1.0 μmol/L. Notably, it uniquely targets Aurora A kinase. The study explores KW-2449's potential in combating leukemia in cell lines with constitutively active FLT3 and in those with wild-type FLT3. In FLT3-ITD positive MOLM-13 cells, KW-2449 reduces phosphorylated FLT3 and STAT5, leading to G1 arrest and apoptosis. It also shows strong inhibitory activity against 32D cells with various FLT3 mutations and inhibits the growth of wild-type RS4;11 cells, reducing phosphorylated Histone H3 and inducing G2/M arrest and apoptosis.

In vivo studies in SCID mice with MOLM-13 leukemia demonstrate dose-dependent tumor growth inhibition with KW-2449, with complete remission at a dose of 20 mg/kg without significant weight loss. PK/PD studies show a reduction in phosphorylated FLT3 and STAT5 levels in tumors post-treatment. Furthermore, oral administration of 20 mg/kg KW-2449 extends survival in xenograft models with MOLM-13 or 32D/FLT3-D835Y cells. KW-2449 also exhibits concentration-dependent growth inhibition in primary AML samples with FLT3 mutations, correlating with reduced P-FLT3 and P-STAT5 levels.

Given its potent and unique kinase inhibition profile, KW-2449 is anticipated to be effective in treating AML with FLT3 mutations, FLT3 wild-type AML, imatinib-resistant CML, ALL, and other hematological malignancies. It is currently under investigation in a Phase I clinical trial for patients with relapsed or refractory AML, MDS, CML, and ALL.

How to Use Synapse Database to Search and Analyze Translational Medicine Data?

The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

图片包含 应用程序

描述已自动生成

Click on the image below to go directly to the Translational Medicine search interface.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成